Development of a Dichloroacetic Acid-Hemoglobin Conjugate as a Potential Targeted Anti-Cancer Therapeutic

This work focuses on conjugating the anticancer drug dichloroacetic acid (DCA) to the monocyte/macrophage targeting protein hemoglobin (Hb). The DCA-Hb conjugate carries approximately 12 DCA molecules per Hb tetramer, and binds to haptoglobin (Hp) forming stable DCA-Hb-Hp complexes, in a similar manner to unmodified Hb. The results of this study show that DCA-Hb-Hp is taken up by the monocytic cancer cell line THP-1, where it depolarizes the mitochondrial membrane potential, thereby inhibiting cancerous cell growth at a comparable level to free DCA. Taken together, the results of this study show promise for the use of the DCA-Hb conjugate as a potential therapeutic to treat monocytic leukemia. Biotechnol. Bioeng. 2011; 108: 1413-1420. (C) 2011 Wiley Periodicals, Inc.